Foghorn Therapeutics Inc (FHTX)vsRevolution Medicines Inc (RVMD)
FHTX
Foghorn Therapeutics Inc
$4.42
-1.56%
HEALTHCARE · Cap: $337.90M
RVMD
Revolution Medicines Inc
$203.77
+0.21%
HEALTHCARE · Cap: $44.44B
Smart Verdict
WallStSmart Research — data-driven comparison
Foghorn Therapeutics Inc generates 4851% more annual revenue ($36.74M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -175.8%. FHTX earns a higher WallStSmart Score of 28/100 (F).
FHTX
Avoid28
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 112.7% year-over-year
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -470.4% — below average capital efficiency
Trading at 16.8x book value
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : FHTX
The strongest argument for FHTX centers on Revenue Growth, Debt/Equity. Revenue growth of 112.7% demonstrates continued momentum.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : FHTX
The primary concerns for FHTX are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : RVMD
The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.
Key Dynamics to Monitor
FHTX profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.
FHTX carries more volatility with a beta of 2.83 — expect wider price swings.
FHTX is growing revenue faster at 112.7% — sustainability is the question.
FHTX generates stronger free cash flow (-19M), providing more financial flexibility.
Bottom Line
FHTX scores higher overall (28/100 vs 24/100) and 112.7% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Foghorn Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops drugs that target genetically determined dependencies within the chromatin regulatory system. The company is headquartered in Cambridge, Massachusetts.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?